Cognitive change is one of the most common—and most misunderstood—symptoms of multiple sclerosis. In this episode, host Brett Drummond speaks with Dr. Vicki Levitt (Columbia University) and Dr. Tom Fuchs (MS Center Amsterdam) about the state of cognition research, why measurement still lags behind clinical need, and how new tools may change the field forever.

At every stage of the MS journey, nurses are the steady link between patients, families, and the healthcare team.

In this episode, host Brett Drummond speaks with Amy Perrin Ross, MS Specialist Nurse and Program Coordinator at Loyola University Chicago (USA), and Miguel Ángel Cortés-Vicente, Multiple Sclerosis Consultant Nurse at CEMCAT – Centre d'Esclerosi Múltiple de Catalunya (Spain), about the evolving role of MS nurses — from care coordination and patient engagement to leadership in research and innovation.

They share insights from the 2025 ECTRIMS Congress Nurse Sessions, exploring how nurses are advancing health literacy, supporting shared decision-making, and integrating AI to improve patient care.

While much of MS care focuses on physical symptoms, mental health challenges—like depression, anxiety, loneliness, and stigma—often go under-recognised.

In this episode, host Brett Drummond speaks with Dr. Rebecca MaGuire, psychologist and MS researcher at Maynooth University, who also lives with MS herself. Together they discuss why mental health must become a core part of MS care, what the latest research reveals, and how clinicians and communities can better support emotional wellbeing throughout the MS journey.

Patient Community Day 2025 set a new attendance record, highlighting the growing desire among people living with MS to connect with experts leading the charge in understanding the disease and advancing effective treatments.

After the event wrapped up in Barcelona, host Brett Drummond caught up with Julie Petrin, Director of Impact and Evaluation at MS Canada and a person living with MS, and Non Helena Smit, CEO of MS South Africa, to reflect on key takeaways and share what they're looking forward to at next year's event in Toronto.

At the late breaking abstracts session at ECTRIMS 2025 in Barcelona, the CCMR-Two trial revealed promising results for myelin repair in MS using the diabetes drug metformin and the antihistamine clemastine. Straight from his presentation, trial lead Dr. Nick Cunniffe of the University of Cambridge sat down with host Brett Drummond of MStranslate to discuss the full results of CCMR-Two, our current understanding of myelin repair biology, and the next steps for remyelination clinical trials and potential future MS therapies.

On the final day of ECTRIMS 2025 in Barcelona, the spotlight turned to MS treatment, including long-awaited clinical trial results. Dr. Sharmilee Gnanapavan, Consultant Neurologist at Barts Health and Princess Alexandra Hospital NHS Trust (UK), joins host Brett Drummond to reflect on key takeaways from the 41st Congress and what the MS community might look forward to at MSToronto 2026.

Dr. Barry Singer, Director and Founder of The MS Center for Innovations in Care, joins host Brett Drummond to discuss the key takeaways unveiled on the second day of ECTRIMS 2025 in Barcelona.

The 41st Congress of ECTRIMS opened in Barcelona with Professor Maria Pia Amato of the University of Florence delivering the ECTRIMS Lecture. In this conversation with host Brett Drummond, she highlights the key takeaways from Day One of ECTRIMS 2025 and shares insights on cognition and what's shaping the future of multiple sclerosis research and care.

Direct from Barcelona, listen to Alvaro Cobo Calvo from the Multiple Sclerosis Center of Catalonia (Cemcat) and host Brett Drummond discuss the highlights of ECTRIMS 2025 Pre-Day, which is focused on specialised topics in MS and related neuroinflammatory autoimmune diseases such as MOGAD and NMOSD.

The 2024 Revisions of the McDonald Diagnostic Criteria for MS have been published in The Lancet Neurology. What do these changes mean for clinical practice?

In this episode, we are joined by two authors of the paper: Prof. Xavier Montalban, Chair of the International Advisory Committee on Clinical Trials in MS (IACCTMS), and Dr. Jiwon Oh of the University of Toronto. Together with host Brett Drummond of MStranslate, they discuss the significance of the updates, how these changes could expedite diagnosis and reduce misdiagnosis, and what they mean for the future of MS care globally.

Reference: Montalban, X. et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. https://doi.org/10.1016/S1474-4422(25)00270-4 (2025).